Eurazeo: finalizes its investment in PanTera

(CercleFinance.com) - The Nov Santé Actions Non Cotées fund, managed by Eurazeo, announces the finalization of its second growth equity investment in PanTera.


Eurazeo and Kurma Partners, its Venture Santé subsidiary, are taking a minority stake in the company, alongside EQT, the lead investor in the transaction.

PanTera aims to produce Actinium-225 on a large scale. The Belgian manufacturing site should be able to provide a large-scale supply by 2028. PanTera plans to produce enough Actinium-225 to treat 100,000 patients a year by 2029.

'This radioisotope has particularly promising characteristics in the fight against cancer, given its ability to eliminate cancer cells more thoroughly while sparing surrounding healthy tissue as much as possible. Numerous clinical trials are currently underway in the treatment of certain cancers and leukemias, notably neuroendocrine and prostate cancers', says the group.

Copyright (c) 2024 CercleFinance.com. All rights reserved.